Use of gemcitabine and nab-paclitaxel as a third-line treatment following failure of first line gemcitabine for advanced pancreatic adenocarcinoma

被引：0
|
作者：
McNulty, M. [1 ]
Dean, A. [2 ]
Das, A. [1 ]
Gordon, M. [1 ]
机构：
[1] St John God Hosp Subiaco, Perth, WA, Australia
[2] St John God Hosp Subiaco, Subiaco, WA, Australia
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P - 147
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
    Mita, Naoki
    Iwashita, Takuji
    Uemura, Shinya
    Yoshida, Kensaku
    Iwasa, Yuhei
    Ando, Nobuhiro
    Iwata, Keisuke
    Okuno, Mitsuru
    Mukai, Tsuyoshi
    Shimizu, Masahito
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
  • [22] Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment
    Angelica Petrillo
    Annalisa Pappalardo
    Luca Pompella
    Giuseppe Tirino
    Filomena Calabrese
    Maria Maddalena Laterza
    Marianna Caterino
    Anna Ventriglia
    Michele Orditura
    Giovanni Conzo
    Carlo Molino
    Fortunato Ciardiello
    Maria Biglietto
    Ferdinando De Vita
    Medical Oncology, 2019, 36
  • [23] Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment
    Petrillo, Angelica
    Pappalardo, Annalisa
    Pompella, Luca
    Tirino, Giuseppe
    Calabrese, Filomena
    Laterza, Maria Maddalena
    Caterino, Marianna
    Ventriglia, Anna
    Orditura, Michele
    Conzo, Giovanni
    Molino, Carlo
    Ciardiello, Fortunato
    Biglietto, Maria
    De Vita, Ferdinando
    MEDICAL ONCOLOGY, 2019, 36 (10)
  • [24] Modified FOLFIRINOX as a second -line treatment in pancreatic adenocarcinoma following gemcitabine plus nab-paclitaxel failure in patients with performance status two or less
    Das, A.
    Dean, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] Second-line treatment with modified FOLFIRINOX in patients with pancreatic adenocarcinoma who have failed first-line treatment with gemcitabine and nab-paclitaxel
    McSweeney, T.
    Das, A.
    O'Mahony, A.
    O'Tighearnaigh, F.
    O'Byrne, L.
    Feely, M.
    Passmore, E.
    Keane, S.
    Lanigan, S.
    Fitzgerald, S.
    Browne, T.
    De Beer, V.
    Dean, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S133 - S133
  • [26] Nab-paclitaxel and gemcitabine for the treatment of pancreatic adenocarcinoma at an academic center.
    Gahvari, Zhubin
    LoConte, Noelle K.
    Lubner, Sam Joseph
    Mulkerin, Daniel
    Cho, Clifford Suhyun
    Winslow, Emily
    Weber, Sharon M.
    Deming, Dustin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Efficacy of SBP-101, in combination with gemcitabine and nab-paclitaxel, in first-line treatment of metastatic pancreatic ductal adenocarcinoma
    Kotasek, Dusan
    Nagrial, Adnan
    Lumba, Sumit
    Tebbutt, Niall C.
    George, Thomas J.
    Smith, Sheri Lynn
    Gagnon, Suzanne
    Cullen, Michael T.
    Walker, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [28] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Yuan Zong
    Jiajia Yuan
    Zhi Peng
    Ming Lu
    Xicheng Wang
    Lin Shen
    Jun Zhou
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 1529 - 1536
  • [29] Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer
    Petrioli, Roberto
    Torre, Pamela
    Pesola, Guido
    Paganini, Giovanni
    Paolelli, Loretta
    Miano, Salvatora Tindara
    Martellucci, Ignazio
    Francini, Guido
    Francini, Edoardo
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (04) : 647 - 651
  • [30] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Chen, Shuling
    Li, Jiaxin
    Dong, Aoran
    Liu, Zelong
    Zhu, Meiyan
    Jin, Meng
    Wei, Guangyan
    Wu, Shuang
    Wang, Yan
    Chen, Yong
    Peng, Zhenwei
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
12345